ARS Pharmaceuticals, Inc. 8-K

What Happened
ARS Pharmaceuticals, Inc. (filed on Form 8-K, Item 5.02) announced that on July 7, 2026 its Board appointed the company’s President, Donn Casale, as Chief Executive Officer, effective immediately. Mr. Casale replaces Richard Lowenthal, whose employment was terminated without cause and effective immediately after being notified on July 6, 2026. Mr. Casale was also appointed to the Board as a Class III director, to serve until the 2029 annual meeting. The filing incorporates Mr. Casale’s biographical information by reference to the Company’s May 13, 2026 Form 8-K.

Key Details

• Appointment effective: July 7, 2026 (CEO: Donn Casale).
• Departure/termination: Richard Lowenthal notified July 6, 2026; terminated without cause, effective immediately.
• Board role: Casale concurrently named Class III director through the 2029 annual meeting.
• Biographical information: Casale’s bio is included by reference to the Company’s May 13, 2026 Form 8-K; this report does not detail compensation or severance terms.

Why It Matters
A CEO change is material for investors because it can affect strategy, operations, and investor confidence. This was an internal promotion (President to CEO), which may indicate continuity in leadership and strategy. The immediate, without-cause termination of the prior CEO is a notable governance event; investors should watch for subsequent disclosures about strategic direction, executive compensation, or any operational changes tied to the leadership transition.